Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Presentation TCT 2023

TCT 376: Association between Thrombogenicity and Systolic Heart Failure and Their Clinical Implication after Percutaneous Coronary Intervention

Presenter: Jun Hwan Cho

October 26, 2023

Presentation TCT 2022

Device Thrombogenicity

Presenter: Prem Midha

September 17, 2022

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

Presentation TCT 2019

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Presenter: Usman Baber

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

Impact of Stent Design Features on Vascular Healing and Surface Thrombogenicity: What Really Matters?

Presenter: Greg Kaluza

September 26, 2019

News Conference News TCT 2018

Novel LAA Closure Device Shows Promise in Early Experience

L.A. McKeown

September 22, 2018

News Conference News TCT 2014

Bioabsorbable Polymer DES Represent Evolution to Stenting Platform

September 19, 2014

News Conference News TCT 2012

Promising Outlook for Bioabsorbable Scaffolds, Polymers in Next-Generation Stents

October 24, 2012

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Usman Baber About the TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

September 28, 2019

Advertisement

TCT 376: Association between Thrombogenicity and Systolic Heart Failure and Their Clinical Implication after Percutaneous Coronary Intervention

Device Thrombogenicity

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Impact of Stent Design Features on Vascular Healing and Surface Thrombogenicity: What Really Matters?

Novel LAA Closure Device Shows Promise in Early Experience

Bioabsorbable Polymer DES Represent Evolution to Stenting Platform

Promising Outlook for Bioabsorbable Scaffolds, Polymers in Next-Generation Stents

Dr. C. Michael Gibson Talks With Dr. Usman Baber About the TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content